Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand

Bannakij Lojanapiwat; Choosak Pripatnanont; Vorapot Choonhaklai; Surithorn Soontornpun; Supon Sriplakich; Sunai Leewansangtong; Apirak Santi-ngamkun; Julin Opanuraks; Wisoot Kongcharoensombat; Bhapapak Na-Songkla; Wiroj Raksakul; Chagkrapan Predanon

doi:10.1016/j.prnil.2017.01.002

Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand

Bannakij Lojanapiwat
, Choosak Pripatnanont
, Vorapot Choonhaklai
, Surithorn Soontornpun
, Supon Sriplakich
, Sunai Leewansangtong
, Apirak Santi-ngamkun
, Julin Opanuraks
, Wisoot Kongcharoensombat
, Bhapapak Na-Songkla
, Wiroj Raksakul
, Chagkrapan Predanon

Faculty of Medicine, Chiang Mai University
Faculty of Medicine, Prince of Songkla University
Rajavithi Hospital
Chulalongkorn University
Navamindradhiraj University
Khon Kaen Regional Hospital

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

Treatment options for castration-resistant prostate cancer (CRPC) are available, but clear instructions for the selection of appropriate treatment are lacking. A meeting of urology experts based in Thailand was convened with the following objectives: (1) to reach a consensus and share real-life experiences about how to identify CRPC; (2) to choose the appropriate treatment for CRPC patients; (3) to evaluate disease progression using novel inhibitors of the androgen receptor pathway; (4) to identify the frequency of monitoring disease; and (5) to promote rational use of corticosteroids in CRPC patients. This consensus document can provide guidance to other urologists in Thailand to provide appropriate treatment to metastatic CRPC patients in a timely manner.

Original language	English
Pages (from-to)	1-7
Number of pages	7
Journal	Prostate International
Volume	5
Issue number	1
DOIs	https://doi.org/10.1016/j.prnil.2017.01.002
Publication status	Published - 1 Mar 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Abiraterone acetate
Androgen receptor
Metastatic castration-resistant prostate cancer
Prostate-specific antigen
Urology expert

Access to Document

10.1016/j.prnil.2017.01.002

Cite this

Lojanapiwat, B., Pripatnanont, C., Choonhaklai, V., Soontornpun, S., Sriplakich, S., Leewansangtong, S., Santi-ngamkun, A., Opanuraks, J., Kongcharoensombat, W., Na-Songkla, B., Raksakul, W., & Predanon, C. (2017). Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand. Prostate International, 5(1), 1-7. https://doi.org/10.1016/j.prnil.2017.01.002

@article{94f6ce71ff774d93a2da2d1799ce546f,

title = "Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand",

abstract = "Treatment options for castration-resistant prostate cancer (CRPC) are available, but clear instructions for the selection of appropriate treatment are lacking. A meeting of urology experts based in Thailand was convened with the following objectives: (1) to reach a consensus and share real-life experiences about how to identify CRPC; (2) to choose the appropriate treatment for CRPC patients; (3) to evaluate disease progression using novel inhibitors of the androgen receptor pathway; (4) to identify the frequency of monitoring disease; and (5) to promote rational use of corticosteroids in CRPC patients. This consensus document can provide guidance to other urologists in Thailand to provide appropriate treatment to metastatic CRPC patients in a timely manner.",

keywords = "Abiraterone acetate, Androgen receptor, Metastatic castration-resistant prostate cancer, Prostate-specific antigen, Urology expert",

author = "Bannakij Lojanapiwat and Choosak Pripatnanont and Vorapot Choonhaklai and Surithorn Soontornpun and Supon Sriplakich and Sunai Leewansangtong and Apirak Santi-ngamkun and Julin Opanuraks and Wisoot Kongcharoensombat and Bhapapak Na-Songkla and Wiroj Raksakul and Chagkrapan Predanon",

note = "Publisher Copyright: {\textcopyright} 2017",

year = "2017",

month = mar,

day = "1",

doi = "10.1016/j.prnil.2017.01.002",

language = "English",

volume = "5",

pages = "1--7",

journal = "Prostate International",

issn = "2287-8882",

publisher = "Elsevier B.V.",

number = "1",

}

Lojanapiwat, B, Pripatnanont, C, Choonhaklai, V, Soontornpun, S, Sriplakich, S, Leewansangtong, S, Santi-ngamkun, A, Opanuraks, J, Kongcharoensombat, W, Na-Songkla, B, Raksakul, W & Predanon, C 2017, 'Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand', Prostate International, vol. 5, no. 1, pp. 1-7. https://doi.org/10.1016/j.prnil.2017.01.002

TY - JOUR

T1 - Management of metastatic castration-resistant prostate cancer

T2 - Insights from urology experts in Thailand

AU - Lojanapiwat, Bannakij

AU - Pripatnanont, Choosak

AU - Choonhaklai, Vorapot

AU - Soontornpun, Surithorn

AU - Sriplakich, Supon

AU - Leewansangtong, Sunai

AU - Santi-ngamkun, Apirak

AU - Opanuraks, Julin

AU - Kongcharoensombat, Wisoot

AU - Na-Songkla, Bhapapak

AU - Raksakul, Wiroj

AU - Predanon, Chagkrapan

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Treatment options for castration-resistant prostate cancer (CRPC) are available, but clear instructions for the selection of appropriate treatment are lacking. A meeting of urology experts based in Thailand was convened with the following objectives: (1) to reach a consensus and share real-life experiences about how to identify CRPC; (2) to choose the appropriate treatment for CRPC patients; (3) to evaluate disease progression using novel inhibitors of the androgen receptor pathway; (4) to identify the frequency of monitoring disease; and (5) to promote rational use of corticosteroids in CRPC patients. This consensus document can provide guidance to other urologists in Thailand to provide appropriate treatment to metastatic CRPC patients in a timely manner.

AB - Treatment options for castration-resistant prostate cancer (CRPC) are available, but clear instructions for the selection of appropriate treatment are lacking. A meeting of urology experts based in Thailand was convened with the following objectives: (1) to reach a consensus and share real-life experiences about how to identify CRPC; (2) to choose the appropriate treatment for CRPC patients; (3) to evaluate disease progression using novel inhibitors of the androgen receptor pathway; (4) to identify the frequency of monitoring disease; and (5) to promote rational use of corticosteroids in CRPC patients. This consensus document can provide guidance to other urologists in Thailand to provide appropriate treatment to metastatic CRPC patients in a timely manner.

KW - Abiraterone acetate

KW - Androgen receptor

KW - Metastatic castration-resistant prostate cancer

KW - Prostate-specific antigen

KW - Urology expert

UR - https://www.scopus.com/pages/publications/85012939668

U2 - 10.1016/j.prnil.2017.01.002

DO - 10.1016/j.prnil.2017.01.002

M3 - Review article

AN - SCOPUS:85012939668

SN - 2287-8882

VL - 5

SP - 1

EP - 7

JO - Prostate International

JF - Prostate International

IS - 1

ER -

Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this